LMP-1/LMP-2 CTLs (Baylor College of Medicine)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameLMP-1/LMP-2 CTLs (Baylor College of Medicine)
Drug Alias NameLMP-1/LMP-2 specific cytotoxic T-lymphocytes (Baylor College of Medicine)LMP-1/LMP-2 specific cytotoxic T-lymphocytes (Baylor College of Medicine)Ad5f35LMPd1-2
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionLatent membrane protein 1 inhibitorsLatent membrane protein 2 inhibitors
TargetsLatent membrane protein 2Latent membrane protein 1
Therapy Area/IndicationsLymphoproliferative DisordersNasopharyngeal CarcinomaLeiomyosarcoma +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBaylor College Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesBaylor College Of Medicine
Inactive CompaniesN/A
Active IndicationsLymphoproliferative DisordersNasopharyngeal CarcinomaLeiomyosarcoma +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A